GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medifast Inc (MED) [hlAlert]

Rating:
Outperform
MED
up 6.69 %

Medifast Inc (MED) rated Outperform with price target $34 by Imperial Capital

Posted on: Friday,  Aug 8, 2014  12:00 AM ET by Imperial Capital

Imperial Capital rated Outperform Medifast Inc (NYSE: MED) on 08/08/2014. Previously Imperial Capital rated Outperform Medifast Inc (NYSE: MED) on 09/06/2013.,
when the stock price was $26.14. Since then, Medifast Inc has gained 6.69% as of 01/11/2016's recent price of $27.89.
If you would have followed the previous Imperial Capital's recommendation on MED, you would have gained 6.69% of your investment in 857 days.

Medifast, Inc. (Medifast) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The Company?s product lines include weight and disease management, meal replacement, and vitamins primarily manufactured in its modern, the United States Food and Drug Administration (FDA) approved facility in Owings Mills, Maryland. The Company?s operations are primarily conducted through five of its wholly owned subsidiaries, Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSF), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. The Company offers a variety of weight and disease management products under the Medifast brand and for select private label customers. It's distribution channels include Medifast Direct, Take Shape for Life, Medifast Weight Control Centers and Medifast Physicians.

Imperial Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/7/2014 8:25 AM Buy
None
30.56 32.00
as of 10/17/2014
1 Week up  2.63 %
1 Month down  -7.18 %
3 Months up  7.16 %
1 YTD up  19.13 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/8/2014 12:00 AM Buy
None
26.15 34.00
9/6/2013 9:25 AM Buy
None
26.14 30.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy